- Effective July 13, Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner.
- Effective July 7, Cycle Pharmaceuticals’ PHYRAGO™ (dasatinib) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner
- Biologics by McKesson became the exclusive specialty pharmacy provider for DECNUPAZ, an intravenous therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm.
- This Pharmaceutical Commerce article explores how purpose‑built patient hubs can streamline access, reduce barriers and better support the complex needs of cell and gene therapy patients. It was co‑authored by Ela Lourido, vice president and general manager of Biologics by McKesson, and Joe DePinto, head of cell, gene and advanced therapies for InspiroGene by McKesson.
- Read about how Biologics by McKesson uses proactive pharmacy care and personalized support to help patients stay on therapies, reduce costs and improve outcomes.
- Biologics by McKesson became the exclusive specialty pharmacy provider for ZYCUBO, the first FDA-approved treatment for pediatric patients with Menkes disease.